Quad Pharmaceuticals sale
T&S Holding signs a non-binding letter of intent to acquire "substantially all" the assets of injectable generics firm Quad, parent Pharmaceutical Resources, Inc. announces Jan. 14. Quad has nine active ANDAs remaining after asking FDA to withdraw 97 of its previous 106 ANDAs in November. In return for Quad's assets, privately-held T&S Holding will assume debt of approximately $3 mil., make future payments of up to $1.55 mil. based on sales of the products acquired, and make cash payments totaling $750,000. The deal is expected to close in April 1992, subject to T&S Holding obtaining financing. PRI announced last September that Quad's operations were being discontinued and that it planned to sell the generic injectables subsidiary ("The Pink Sheet" Sept. 30, T&G-11)....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth